NCT02286687View on ClinicalTrials.gov

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 22, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Malignant NeoplasmATM Gene MutationBRCA1 Gene MutationBRCA2 Gene MutationMetastatic Malignant NeoplasmPALB2 Gene MutationRecurrent Malignant NeoplasmRefractory Malignant Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Talazoparib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER